von Hippel-Lindau disease: An Update
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Purpose of the Review: In this review we discuss the key molecular and clinical developments in VHL disease that have the potential to impact on the natural history of the disease and improve patient outcomes Recent Findings: Identifiable mutations in VHL underlie most cases of VHL and define clear genotype-phenotype correlations. Detailed clinical and molecular characterisation has allowed the implementation of lifelong screening programmes that have improved clinical outcomes. Functional characterisation of the VHL protein complex has revealed its role in oxygen sensing and the mechanisms of tumourigenesis that are now being exploited to develop novel therapies for VHL and renal cancer. Summary: The molecular and cellular landscape of VHL associated tumours is revealing new opportunities to modify the natural history of the disease and develop therapies. Drugs are now entering clinical trials and combined with improved clinical and molecular diagnosis, and lifelong surveillance programmes, further progress towards reducing the morbidity and mortality associated with VHL disease is anticipated.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
2167-4876
Volume Title
Publisher
Publisher DOI
Rights
Sponsorship
Department of Health (via National Institute for Health Research (NIHR)) (NF-SI-0616-10035)